No connection

Search Results

LEGN vs LIVN

LEGN
Legend Biotech Corporation
BEARISH
Price
$18.16
Market Cap
$3.36B
Sector
Healthcare
AI Confidence
85%
LIVN
LivaNova PLC
NEUTRAL
Price
$62.78
Market Cap
$3.43B
Sector
Healthcare
AI Confidence
70%

Valuation

P/E Ratio
LEGN
--
LIVN
--
Forward P/E
LEGN
15.79
LIVN
13.71
P/B Ratio
LEGN
3.35
LIVN
2.86
P/S Ratio
LEGN
3.26
LIVN
2.47
EV/EBITDA
LEGN
-48.64
LIVN
12.54

Profitability

Gross Margin
LEGN
20.03%
LIVN
68.01%
Operating Margin
LEGN
-6.72%
LIVN
12.97%
Profit Margin
LEGN
-28.85%
LIVN
-17.47%
ROE
LEGN
-29.06%
LIVN
-19.24%
ROA
LEGN
-5.01%
LIVN
5.17%

Growth

Revenue Growth
LEGN
64.2%
LIVN
12.1%
Earnings Growth
LEGN
--
LIVN
-45.6%

Financial Health

Debt/Equity
LEGN
0.41
LIVN
0.36
Current Ratio
LEGN
1.96
LIVN
1.36
Quick Ratio
LEGN
1.88
LIVN
1.05

Dividends

Dividend Yield
LEGN
--
LIVN
--
Payout Ratio
LEGN
0.0%
LIVN
0.0%

AI Verdict

LEGN BEARISH

LEGN exhibits severe financial instability as evidenced by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company shows impressive top-line revenue growth of 64.20%, this is offset by consistent earnings misses (average surprise of -66.26% over the last 4 quarters) and a devastating technical trend (0/100). There is a stark disconnect between the bullish analyst target of $57.22 and the actual price performance, which has declined over 41% in the last year. The stock currently behaves as a high-risk speculative asset with failing fundamental health markers.

Strengths
Strong YoY revenue growth of 64.20%
Low Debt/Equity ratio of 0.41
Healthy liquidity with a Current Ratio of 1.96
Risks
Critical Piotroski F-Score (1/9) indicating fundamental weakness
Severe technical breakdown with 0/100 trend score
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
LIVN NEUTRAL

LIVN presents a stark contrast between poor deterministic health and strong market momentum. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, and the technical trend is currently bearish. However, the company maintains strong gross margins (68.01%) and a low debt-to-equity ratio (0.36), while analysts remain bullish with a target price of $79.64. The valuation appears attractive on a PEG basis (0.72), but the negative net profit margin and ROE suggest operational inefficiencies or significant non-operating losses.

Strengths
Strong Gross Margin of 68.01% indicating high product value
Low Debt/Equity ratio (0.36) suggesting a conservative capital structure
Consistent double-digit revenue growth (12.10% YoY)
Risks
Very weak Piotroski F-Score (2/9) signaling deteriorating fundamental health
Negative Profit Margin (-17.47%) and ROE (-19.24%)
Severe volatility in earnings, including a massive surprise miss in May 2025

Compare Another Pair

LEGN vs LIVN: Head-to-Head Comparison

This page compares Legend Biotech Corporation (LEGN) and LivaNova PLC (LIVN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile